|
Name |
2,4,6-Triphenylpyridine
|
Molecular Formula | C23H17N | |
IUPAC Name* |
2,4,6-triphenylpyridine
|
|
SMILES |
C1=CC=C(C=C1)C2=CC(=NC(=C2)C3=CC=CC=C3)C4=CC=CC=C4
|
|
InChI |
InChI=1S/C23H17N/c1-4-10-18(11-5-1)21-16-22(19-12-6-2-7-13-19)24-23(17-21)20-14-8-3-9-15-20/h1-17H
|
|
InChIKey |
FRZHWQQBYDFNTH-UHFFFAOYSA-N
|
|
Synonyms |
2,4,6-Triphenylpyridine; 580-35-8; Pyridine, 2,4,6-triphenyl-; 2,4,6-Triphenyl-pyridin; 2,4,6-Triphenyl-pyridine; 2,6-Triphenylpyridine; NSC2245; Pyridine,4,6-triphenyl-; 2,4,6,-triphenylpyridine; CHEMBL27882; SCHEMBL960513; YSCH0044; DTXSID30206730; BCP15453; NSC 2245; NSC-2245; ZINC1541473; MFCD00014630; STK391423; AKOS001031352; CS-W012081; NCGC00331413-01; UPCMLD0ENAT0505-1329:001; DB-019855; FT-0609919; T3394; T72658; AB01099975-04; 2.4.6-TRICHLORO-1.3.5-TRIPHENYLBORAZINE; A831709
|
|
CAS | 580-35-8 | |
PubChem CID | 136370 | |
ChEMBL ID | CHEMBL27882 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 307.4 | ALogp: | 5.8 |
HBD: | 0 | HBA: | 1 |
Rotatable Bonds: | 3 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 12.9 | Aromatic Rings: | 4 |
Heavy Atoms: | 24 | QED Weighted: | 0.444 |
Caco-2 Permeability: | -4.747 | MDCK Permeability: | 0.00001470 |
Pgp-inhibitor: | 0.896 | Pgp-substrate: | 0.97 |
Human Intestinal Absorption (HIA): | 0.003 | 20% Bioavailability (F20%): | 0.997 |
30% Bioavailability (F30%): | 0.276 |
Blood-Brain-Barrier Penetration (BBB): | 0.247 | Plasma Protein Binding (PPB): | 101.23% |
Volume Distribution (VD): | 0.78 | Fu: | 0.74% |
CYP1A2-inhibitor: | 0.979 | CYP1A2-substrate: | 0.133 |
CYP2C19-inhibitor: | 0.607 | CYP2C19-substrate: | 0.047 |
CYP2C9-inhibitor: | 0.291 | CYP2C9-substrate: | 0.594 |
CYP2D6-inhibitor: | 0 | CYP2D6-substrate: | 0.088 |
CYP3A4-inhibitor: | 0.044 | CYP3A4-substrate: | 0.17 |
Clearance (CL): | 5.948 | Half-life (T1/2): | 0.066 |
hERG Blockers: | 0.203 | Human Hepatotoxicity (H-HT): | 0.051 |
Drug-inuced Liver Injury (DILI): | 0.531 | AMES Toxicity: | 0.552 |
Rat Oral Acute Toxicity: | 0.403 | Maximum Recommended Daily Dose: | 0.269 |
Skin Sensitization: | 0.651 | Carcinogencity: | 0.706 |
Eye Corrosion: | 0.01 | Eye Irritation: | 0.959 |
Respiratory Toxicity: | 0.034 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001050 | 0.420 | D0AA2D | 0.455 | ||||
ENC001402 | 0.396 | D09GOS | 0.431 | ||||
ENC000321 | 0.378 | D0M9DC | 0.402 | ||||
ENC000732 | 0.368 | D0U3ED | 0.398 | ||||
ENC001018 | 0.364 | D03DEI | 0.393 | ||||
ENC003032 | 0.354 | D0Q3YO | 0.368 | ||||
ENC004519 | 0.340 | D0VU2X | 0.356 | ||||
ENC004518 | 0.340 | D01VMO | 0.345 | ||||
ENC004517 | 0.340 | D00SLY | 0.336 | ||||
ENC001752 | 0.339 | D09ZOQ | 0.333 |